ME03410B - Heterociklična jedinjenja - Google Patents

Heterociklična jedinjenja

Info

Publication number: ME03410B
Authority: ME; Montenegro
Prior art keywords: heterocyclic compound; heterocyclic; compound
Prior art date: 2010-02-17

Application number

MEP-2019-152A

Other languages

German (de)

English (en)

French (fr)

Inventor

Misaki Homma

Toru Miyazaki

Yuya Oguro

Osamu Kurasawa

Original Assignee

Takeda Pharmaceuticals Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-02-17

Filing date

2011-02-16

Publication date

2020-01-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44482985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME03410(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-02-16 Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co

2020-01-20 Publication of ME03410B publication Critical patent/ME03410B/me

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

MEP-2019-152A 2010-02-17 2011-02-16 Heterociklična jedinjenja ME03410B (me)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
JP2010031899		2010-02-17
JP2010131950		2010-06-09
EP11744685.6A EP2540728B1 (en)	2010-02-17	2011-02-16	Heterocyclic compound
PCT/JP2011/053303 WO2011102399A1 (ja)	2010-02-17	2011-02-16	複素環化合物

Publications (1)

Publication Number	Publication Date
ME03410B true ME03410B (me)	2020-01-20

Family

ID=44482985

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-2019-152A ME03410B (me)	2010-02-17	2011-02-16	Heterociklična jedinjenja

Country Status (37)

Country	Link
US (6)	US8722660B2 (me)
EP (2)	EP3533797B1 (me)
JP (1)	JP5689454B2 (me)
KR (1)	KR101735868B1 (me)
CN (1)	CN102844320B (me)
AU (1)	AU2011216404B2 (me)
BR (1)	BR112012020311B1 (me)
CA (1)	CA2790284C (me)
CL (1)	CL2012002250A1 (me)
CO (1)	CO6592104A2 (me)
CR (1)	CR20120448A (me)
CY (1)	CY1121792T1 (me)
DK (1)	DK2540728T3 (me)
DO (1)	DOP2012000224A (me)
EA (1)	EA020724B1 (me)
EC (1)	ECSP12012160A (me)
ES (1)	ES2733221T3 (me)
GE (1)	GEP20146202B (me)
HR (1)	HRP20190947T1 (me)
HU (1)	HUE043514T2 (me)
IL (1)	IL221442A0 (me)
LT (1)	LT2540728T (me)
MA (1)	MA34064B1 (me)
ME (1)	ME03410B (me)
MX (1)	MX353500B (me)
MY (1)	MY164776A (me)
NZ (1)	NZ602089A (me)
PE (1)	PE20130184A1 (me)
PH (1)	PH12012501650B1 (me)
PL (1)	PL2540728T3 (me)
PT (1)	PT2540728T (me)
RS (1)	RS58796B1 (me)
SG (1)	SG183304A1 (me)
SI (1)	SI2540728T1 (me)
SM (1)	SMT201900385T1 (me)
TN (1)	TN2012000401A1 (me)
WO (1)	WO2011102399A1 (me)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG187795A1 (en) *	2010-08-11	2013-03-28	Millennium Pharm Inc	Heteroaryls and uses thereof
EP3100742B1 (en)	2014-01-31	2020-05-20	Carna Biosciences Inc.	Anticancer agent composition comprising a cdc7 inhibitor and a wee1 inhibitor
TW201620879A (zh)	2014-04-28	2016-06-16	杜邦股份有限公司	除草性經取代之３－苯基－４－氟基苯甲醯基吡唑
US10174032B2 (en) *	2014-05-05	2019-01-08	Signalrx Pharmaceuticals, Inc.	Heterocyclic compound classes for signaling modulation
CA3105722C (en)	2015-12-07	2022-10-11	Zymergen Inc.	Microbial strain improvement by a htp genomic engineering platform
CN109311868B (zh)	2015-12-22	2022-04-01	尚医治疗有限责任公司	用于治疗癌症和炎性疾病的化合物
ES2884398T3 (es) *	2016-03-28	2021-12-10	Takeda Pharmaceuticals Co	Formas cristalinas de 2-[(2s)-1-azabiciclo[2.2.2]oct-2-il]-6-(3-metil-1H-pirazol-4-il)tieno[3,2-d]pirimidin-4(3H)-ona hemihidrato
EA035560B1 (ru) *	2016-07-28	2020-07-07	Такеда Фармасьютикал Компани Лимитед	Кристаллические формы гемигидрата 2-[(2s)-1-азабицикло[2.2.2]окт-2-ил]-6-(3-метил-1h-пиразол-4-ил)тиено[3,2- d]пиримидин-4(3h)-она
EP3538523B1 (en)	2016-11-08	2021-05-19	Cancer Research Technology Limited	Pyrimidinone derivatives as cdc7 inhibitors
US11155879B2 (en) *	2017-03-01	2021-10-26	Takeda Pharmaceutical Company Limited	Method of predicting effects of CDC7 inhibitor
CN112409373A (zh) *	2017-05-21	2021-02-26	南京正济医药研究有限公司	作为抗癌剂的取代的[5,6]环-4(3h)-嘧啶酮
EA201992780A1 (ru)	2017-06-21	2020-06-02	ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи	Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
US11524957B2 (en) *	2018-04-02	2022-12-13	Takeda Pharmaceutical Company Limited	Process for the synthesis of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one
TWI846703B (zh)	2018-06-19	2024-07-01	日商武田藥品工業股份有限公司	癌症治療方法
IL280130B2 (en) *	2018-07-19	2024-11-01	Takeda Pharmaceuticals Co	Pharmaceutical compositions with a cdc7 inhibitor
EP3898609A1 (en)	2018-12-19	2021-10-27	Shy Therapeutics LLC	Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
KR20220027883A (ko) *	2019-05-30	2022-03-08	치아타이 티안큉 파마수티컬 그룹 주식회사	Cdc7 억제제로서의 테트라사이클릭 화합물
CN114126621A (zh) *	2019-07-19	2022-03-01	武田药品工业株式会社	用于癌症治疗的组合疗法
JP2022546294A (ja) *	2019-08-20	2022-11-04	チアタイティエンチンファーマシューティカルグループカンパニーリミテッド	Ｃｄｃ７阻害剤として使用される四環式化合物
EP4069369A4 (en) *	2019-12-06	2024-02-14	Schrödinger, Inc.	CYCLIC COMPOUNDS AND METHODS OF USE THEREOF
JP2023541047A (ja) *	2020-09-10	2023-09-27	シュレーディンガー，インコーポレイテッド	がんの治療のための複素環式ペリ縮環ｃｄｃ７キナーゼ阻害剤
EP4253388A1 (en) *	2020-11-30	2023-10-04	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Salt form used as cdc7 inhibitor and crystal form thereof
CN112661770B (zh) *	2020-12-24	2022-11-08	南京正济医药研究有限公司	一种化合物及利用其制备取代的[5,6]环-4(3h)-嘧啶酮化合物的方法
WO2022167999A1 (en)	2021-02-08	2022-08-11	Takeda Pharmaceutical Company Limited	Combination therapy for cancer treatment
TW202300150A (zh) *	2021-03-18	2023-01-01	美商薛定諤公司	環狀化合物及其使用方法
CN117120447A (zh) *	2021-03-18	2023-11-24	薛定谔公司	环状化合物和其使用方法
EP4416156A1 (en) *	2021-10-13	2024-08-21	Remix Therapeutics Inc.	Compounds and methods for modulating nucleic acid splicing
WO2025160538A1 (en) *	2024-01-26	2025-07-31	The Board Of Regents Of The University Of Texas System	Compositions and methods for treating hair graying and loss associated with aging
WO2025168620A1 (en)	2024-02-07	2025-08-14	Bayer Aktiengesellschaft	Heteroaryl-substituted 4,5-dihydro-1h-2,4,5-oxadiazines as novel fungicides

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4196207A (en) *	1977-05-23	1980-04-01	Ici Australia Limited	Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
DE19644228A1 (de) *	1996-10-24	1998-04-30	Merck Patent Gmbh	Thienopyrimidine
AUPO721997A0 (en)	1997-06-06	1997-07-03	Queensland Institute Of Medical Research, The	Anticancer compounds
JP2002105081A (ja)	2000-07-28	2002-04-10	Nikken Chem Co Ltd	新規チオフェンニ環化合物
EP1329454A1 (en)	2000-09-29	2003-07-23	Nippon Soda Co., Ltd.	Thienopyrimidine compounds and their salts and process for preparation of both
US6503914B1 (en)	2000-10-23	2003-01-07	Board Of Regents, The University Of Texas System	Thienopyrimidine-based inhibitors of the Src family
US20030096813A1 (en)	2001-04-20	2003-05-22	Jingrong Cao	Compositions useful as inhibitors of GSK-3
JP2005538118A (ja)	2002-08-06	2005-12-15	アストラゼネカアクチボラグ	Ｔｉｅ２（ｔｅｋ）活性を持つ縮合したピリジン及びピリミジン
WO2004111014A1 (en)	2003-06-06	2004-12-23	Vertex Pharmaceuticals Incorporated	Pyrimidine derivatives as modulators of atp-binding cassette transporters
ES2324536T7 (es) *	2003-06-11	2012-03-16	Xention Limited	Derivados de tenopirimidina como inhibidores de los canales de potasio.
US20050032869A1 (en) *	2003-07-08	2005-02-10	Pharmacia Italia S.P.A.	Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US7279575B2 (en)	2003-08-08	2007-10-09	Pfizer Italia S.R.L.	Pyrimidylpyrrole derivatives active as kinase inhibitors
WO2005014572A1 (en)	2003-08-08	2005-02-17	Pharmacia Italia S.P.A.	Pyrimidylpyrrole derivatives active as kinase inhibitors
CA2561977A1 (en) *	2004-03-30	2005-10-13	Chiron Corporation	Substituted thiophene derivatives as anti-cancer agents
EP2520652B1 (en)	2004-04-09	2015-06-10	Genecare Research Institute Co., Ltd	Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes
WO2006078574A2 (en)	2005-01-19	2006-07-27	Merck & Co., Inc.	Mitotic kinesin inhibitors
EP1907398A1 (en)	2005-07-15	2008-04-09	AstraZeneca AB	Therapeutic agents
KR101149954B1 (ko)	2005-08-30	2012-06-01	아사히 가세이 파마 가부시키가이샤	술폰아미드 화합물
FI20055498A0 (fi)	2005-09-16	2005-09-16	Biotie Therapies Corp	Sulfonamidijohdannaisia
US20070142414A1 (en)	2005-12-16	2007-06-21	Pharmacia Italia S.P.A.	N-substituted pyrrolopyridinones active as kinase inhibitors
US7618982B2 (en) *	2005-12-19	2009-11-17	Nerviano Medical Sciences S.R.L.	Heteroarylpyrrolopyridinones active as kinase inhibitors
WO2007102679A1 (en)	2006-03-06	2007-09-13	Je Il Pharmaceutical Co., Ltd.	Novel thienopyrimidine derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same
WO2008082839A2 (en)	2006-12-29	2008-07-10	Abbott Laboratories	Pim kinase inhibitors as cancer chemotherapeutics
US20090030196A1 (en) *	2006-12-29	2009-01-29	Abbott Laboratories	Pim kinase inhibitors as cancer chemotherapeutics
AR065081A1 (es)	2007-01-29	2009-05-13	Xenon Pharmaceuticals Inc	Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica
WO2009001214A2 (en)	2007-06-28	2008-12-31	Pfizer Products Inc.	Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
US20090118276A1 (en)	2007-11-02	2009-05-07	Wyeth	Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
US20110098288A1 (en)	2008-03-11	2011-04-28	Jeremy Major	Sulfonamides as zap-70 inhibitors
PE20091928A1 (es)	2008-05-29	2009-12-31	Bristol Myers Squibb Co	Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
CA2728674A1 (en)	2008-06-26	2009-12-30	Dana-Farber Cancer Institute, Inc.	Signatures and determinants associated with metastasis methods of use thereof
US8691828B2 (en)	2009-03-05	2014-04-08	Takeda Pharmaceutical Company Limited	Thienopyrimidine as CDC7 kinase inhibitors
WO2010126002A1 (ja)	2009-04-28	2010-11-04	塩野義製薬株式会社	ヘテロ環スルホンアミド化合物を含有する医薬
TW201111378A (en)	2009-09-11	2011-04-01	Bayer Schering Pharma Ag	Substituted (heteroarylmethyl) thiohydantoins
CN102481294A (zh)	2009-09-11	2012-05-30	拜耳医药股份有限公司	作为抗癌药物的取代(杂芳基甲基)乙内酰硫脲
JO2978B1 (en)	2009-12-21	2016-03-15	ايلي ليلي اند كومباني	MGLU2 aids

2011
- 2011-02-16 ES ES11744685T patent/ES2733221T3/es active Active
- 2011-02-16 MA MA35205A patent/MA34064B1/fr unknown
- 2011-02-16 SG SG2012059994A patent/SG183304A1/en unknown
- 2011-02-16 JP JP2012500632A patent/JP5689454B2/ja active Active
- 2011-02-16 LT LTEP11744685.6T patent/LT2540728T/lt unknown
- 2011-02-16 BR BR112012020311-8A patent/BR112012020311B1/pt active IP Right Grant
- 2011-02-16 US US13/578,959 patent/US8722660B2/en active Active
- 2011-02-16 PH PH1/2012/501650A patent/PH12012501650B1/en unknown
- 2011-02-16 HR HRP20190947TT patent/HRP20190947T1/hr unknown
- 2011-02-16 CN CN201180019478.3A patent/CN102844320B/zh active Active
- 2011-02-16 WO PCT/JP2011/053303 patent/WO2011102399A1/ja not_active Ceased
- 2011-02-16 RS RS20190639A patent/RS58796B1/sr unknown
- 2011-02-16 DK DK11744685.6T patent/DK2540728T3/da active
- 2011-02-16 GE GEAP201112855A patent/GEP20146202B/en unknown
- 2011-02-16 AU AU2011216404A patent/AU2011216404B2/en active Active
- 2011-02-16 SI SI201131722T patent/SI2540728T1/sl unknown
- 2011-02-16 NZ NZ602089A patent/NZ602089A/en unknown
- 2011-02-16 SM SM20190385T patent/SMT201900385T1/it unknown
- 2011-02-16 PE PE2012001253A patent/PE20130184A1/es active IP Right Grant
- 2011-02-16 EA EA201290800A patent/EA020724B1/ru unknown
- 2011-02-16 EP EP19168244.2A patent/EP3533797B1/en active Active
- 2011-02-16 CA CA2790284A patent/CA2790284C/en active Active
- 2011-02-16 MY MYPI2012003715A patent/MY164776A/en unknown
- 2011-02-16 KR KR1020127024086A patent/KR101735868B1/ko active Active
- 2011-02-16 PT PT11744685T patent/PT2540728T/pt unknown
- 2011-02-16 ME MEP-2019-152A patent/ME03410B/me unknown
- 2011-02-16 HU HUE11744685A patent/HUE043514T2/hu unknown
- 2011-02-16 PL PL11744685T patent/PL2540728T3/pl unknown
- 2011-02-16 MX MX2012009602A patent/MX353500B/es active IP Right Grant
- 2011-02-16 EP EP11744685.6A patent/EP2540728B1/en active Active
2012
- 2012-08-09 TN TNP2012000401A patent/TN2012000401A1/en unknown
- 2012-08-14 CL CL2012002250A patent/CL2012002250A1/es unknown
- 2012-08-14 IL IL221442A patent/IL221442A0/en active IP Right Grant
- 2012-08-15 DO DO2012000224A patent/DOP2012000224A/es unknown
- 2012-08-29 CR CR20120448A patent/CR20120448A/es unknown
- 2012-09-13 CO CO12158066A patent/CO6592104A2/es active IP Right Grant
- 2012-09-17 EC ECSP12012160 patent/ECSP12012160A/es unknown
2014
- 2014-03-24 US US14/223,259 patent/US8921354B2/en active Active
- 2014-03-24 US US14/223,329 patent/US8933069B2/en active Active
- 2014-12-10 US US14/566,157 patent/US9388195B2/en active Active
2016
- 2016-06-08 US US15/176,893 patent/US9655900B2/en active Active
2017
- 2017-04-11 US US15/484,755 patent/US20170209452A1/en not_active Abandoned
2019
- 2019-07-09 CY CY20191100721T patent/CY1121792T1/el unknown

Also Published As

Publication number	Publication date
HUE043514T2 (hu)	2019-08-28
SMT201900385T1 (it)	2019-09-09
PT2540728T (pt)	2019-07-11
JP5689454B2 (ja)	2015-03-25
US20140228352A1 (en)	2014-08-14
EP2540728A1 (en)	2013-01-02
TN2012000401A1 (en)	2014-01-30
KR101735868B1 (ko)	2017-05-15
GEP20146202B (en)	2014-11-25
EP2540728A4 (en)	2013-11-06
US8722660B2 (en)	2014-05-13
ECSP12012160A (es)	2013-03-28
HRP20190947T1 (hr)	2019-07-26
AU2011216404A1 (en)	2012-09-20
CO6592104A2 (es)	2013-01-02
MX353500B (es)	2018-01-16
DK2540728T3 (da)	2019-05-13
US8933069B2 (en)	2015-01-13
CL2012002250A1 (es)	2013-02-08
US20140235615A1 (en)	2014-08-21
BR112012020311A2 (pt)	2017-03-01
CA2790284C (en)	2019-01-08
EA020724B1 (ru)	2015-01-30
EP2540728B1 (en)	2019-04-10
US20130029969A1 (en)	2013-01-31
IL221442A0 (en)	2012-10-31
US9388195B2 (en)	2016-07-12
US20150158882A1 (en)	2015-06-11
MA34064B1 (fr)	2013-03-05
PE20130184A1 (es)	2013-03-09
PL2540728T3 (pl)	2019-09-30
RS58796B1 (sr)	2019-07-31
US9655900B2 (en)	2017-05-23
US20170209452A1 (en)	2017-07-27
PH12012501650A1 (en)	2012-10-22
CA2790284A1 (en)	2011-08-25
MY164776A (en)	2018-01-30
US8921354B2 (en)	2014-12-30
JPWO2011102399A1 (ja)	2013-06-17
SG183304A1 (en)	2012-09-27
SI2540728T1 (sl)	2019-06-28
KR20130001246A (ko)	2013-01-03
PH12012501650B1 (en)	2018-11-07
CN102844320B (zh)	2016-03-23
CY1121792T1 (el)	2020-07-31
EP3533797A1 (en)	2019-09-04
ES2733221T3 (es)	2019-11-28
EP3533797B1 (en)	2023-12-20
NZ602089A (en)	2014-05-30
AU2011216404B2 (en)	2016-04-07
MX2012009602A (es)	2012-12-17
EA201290800A1 (ru)	2013-03-29
LT2540728T (lt)	2019-06-25
US20160310494A1 (en)	2016-10-27
WO2011102399A1 (ja)	2011-08-25
CR20120448A (es)	2012-11-13
DOP2012000224A (es)	2013-01-31
BR112012020311B1 (pt)	2019-01-29
CN102844320A (zh)	2012-12-26

Publication	Publication Date	Title
IL221442A0 (en)	2012-10-31	Heterocyclic compound
ZA201300950B (en)	2014-04-30	Heterocyclic compound
IL225770A0 (en)	2013-06-27	Heterocyclic compounds
PL2521450T3 (pl)	2015-07-31	Grzybobójcze związki heterocykliczne
GB201008134D0 (en)	2010-06-30	Compounds
HUE040101T2 (hu)	2019-02-28	Szubsztituált piridinon-piridinil-származékok
GB201007347D0 (en)	2010-06-16	Compounds
EP2709609A4 (en)	2015-08-26	HETEROCYCLIC COMPOUNDS
EP2649050A4 (en)	2014-04-23	LINKS
GB201002563D0 (en)	2010-03-31	Compounds
GB201008209D0 (en)	2010-06-30	Compounds
GB201001688D0 (en)	2010-03-17	Compounds
GB201017315D0 (en)	2010-11-24	Compound
GB201002911D0 (en)	2010-04-07	Compound
GB201007789D0 (en)	2010-06-23	Novel Compound
GB201002216D0 (en)	2010-03-31	Compounds
GB201001796D0 (en)	2010-03-24	Compounds
GB201008210D0 (en)	2010-06-30	Compounds
GB201007209D0 (en)	2010-06-16	Compound
GB201013507D0 (en)	2010-09-22	Compounds
GB201009514D0 (en)	2010-07-21	Novel heterocyclic compounds
GB201021416D0 (en)	2011-01-26	Novel heterocyclic compounds
GB201008820D0 (en)	2010-07-14	Compound
GB201021228D0 (en)	2011-01-26	Compound
GB201015798D0 (en)	2010-10-27	Compound